Pédiatrie Tumeurs cérébrales SIOP EPENDYMOMA II An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Paris FRANCOIS DOZ
Appareil pulmonaire CHRYSALIS-2 (73841937NSC1001 ) An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-;73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in;Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in;Participants With Advanced Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
Sein Néoadjuvant FIGARO Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse Saint-Cloud
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud
VADS NIVOPOST-OP / GORTEC 2018-01 A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC
Sarcomes STRASS 2 - ETUDE 1809-STBSG A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2) Paris SYLVIE BONVALOT
VADS TG4050.02 A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD